Trial · NCT04908202
Participant flow36
How many started, completed or left each group, period by period.
1 to 20 of 36
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Pre-Treatment Period | STARTED | Placebo-Controlled Period - Deucravacitinib 6 mg QD | 336 | |
| Pre-Treatment Period | STARTED | Placebo-Controlled Period - Placebo | 334 | |
| Pre-Treatment Period | STARTED | Active Treatment Period - Deucravacitinib 6 mg QD | 0 | |
| Pre-Treatment Period | STARTED | Active-Treatment Period - Placebo-Deucravacitinib 6 mg QD | 0 | |
| Pre-Treatment Period | COMPLETED | Placebo-Controlled Period - Deucravacitinib 6 mg QD | 332 | |
| Pre-Treatment Period | COMPLETED | Placebo-Controlled Period - Placebo | 333 | |
| Pre-Treatment Period | COMPLETED | Active Treatment Period - Deucravacitinib 6 mg QD | 0 | |
| Pre-Treatment Period | COMPLETED | Active-Treatment Period - Placebo-Deucravacitinib 6 mg QD | 0 | |
| Pre-Treatment Period | NOT COMPLETED | Placebo-Controlled Period - Deucravacitinib 6 mg QD | 4 | |
| Pre-Treatment Period | NOT COMPLETED | Placebo-Controlled Period - Placebo | 1 | |
| Pre-Treatment Period | NOT COMPLETED | Active Treatment Period - Deucravacitinib 6 mg QD | 0 | |
| Pre-Treatment Period | NOT COMPLETED | Active-Treatment Period - Placebo-Deucravacitinib 6 mg QD | 0 | |
| Placebo-Controlled Treatment Period | STARTED | Placebo-Controlled Period - Deucravacitinib 6 mg QD | 332 | |
| Placebo-Controlled Treatment Period | STARTED | Placebo-Controlled Period - Placebo | 333 | |
| Placebo-Controlled Treatment Period | STARTED | Active Treatment Period - Deucravacitinib 6 mg QD | 0 | |
| Placebo-Controlled Treatment Period | STARTED | Active-Treatment Period - Placebo-Deucravacitinib 6 mg QD | 0 | |
| Placebo-Controlled Treatment Period | COMPLETED | Placebo-Controlled Period - Deucravacitinib 6 mg QD | 309 | |
| Placebo-Controlled Treatment Period | COMPLETED | Placebo-Controlled Period - Placebo | 306 | |
| Placebo-Controlled Treatment Period | COMPLETED | Active Treatment Period - Deucravacitinib 6 mg QD | 0 | |
| Placebo-Controlled Treatment Period | COMPLETED | Active-Treatment Period - Placebo-Deucravacitinib 6 mg QD | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04908202/flow